Key result
BRV-PV cuts severe rotavirus gastroenteritis by ~36% versus placebo in Indian infants.
Why the study?
Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, causing significant morbidity, mortality, and economic burden, necessitating evaluation of a new vaccine.
Does the bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) prevent severe rotavirus gastroenteritis in Indian infants?
RCT (n=7,500)
Double-blind
1:1
Yes
Does the bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) prevent severe rotavirus gastroenteritis in Indian infants?
The BRV-PV vaccine is effective, well-tolerated, and safe in preventing severe rotavirus gastroenteritis in Indian infants.
Answers are grounded in this paper and cite their sources.
Supports BRV-PV use in Indian immunization programs; extends pentavalent rotavirus vaccine efficacy data to South Asian infants.
Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, resulting in enormous morbidity, mortality, and economic burden. A bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) targeting the globally most common strains was developed in India and tested in a randomized, double-blind, placebo-controlled end-point driven Phase III efficacy clinical trial implemented at six sites across India. Infants 6 to 8weeks of age were randomized (1:1) to receive three oral doses of BRV-PV or placebo at 6, 10, and 14weeks of age along with routine vaccines. Home visit surveillance was conducted to detect severe rotavirus gastroenteritis (SRVGE) and safety outcomes until the children reached two years of age. A total of 3749 infants received BRV-PV while 3751 received placebo. At the time of the primary end-point (when the minimum number of cases needed for analysis were accrued) the vaccine efficacy against SRVGE was 36% (95% CI 11.7, 53.6, p=0.0067) in the per protocol (PP) analysis, and 41.9% (95% CI 21.1, 57.3, p=0.0005) in the intent to treat (ITT) analysis. Vaccine efficacy over the entire follow-up period (until children reached two years of age) was 39.5% (95% CI 26.7, 50, p<0.0001) in the PP analysis and 38.8% (95% CI, 26.4, 49, p<0.0001) in the ITT analysis. Vaccine efficacy against the very severe rotavirus cases (VSRVGE, Vesikari score≥16) was 60.5% (95% CI 17.7, 81, p=0.0131) at the time of the primary analysis and 54.7% (95% CI 29.7, 70.8, p=0.0004) for the complete follow-period in the PP population. The incidence of solicited, unsolicited, and serious adverse events were similar in both the vaccine and placebo groups. Likewise, the number of intussusceptions and deaths were similar between both groups. Thus, BRV-PV is an effective, well tolerated and safe vaccine in Indian infants. (Trial registration: Clinical Trials.Gov [NCT 02133690] and Clinical Trial Registry of India [CTRI/2013/05/003667]).
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2017) conducted an RCT in severe rotavirus gastroenteritis (n=7,500). bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) vs. Placebo was evaluated on severe rotavirus gastroenteritis (SRVGE) (Vaccine efficacy 36%, 95% CI 11.7, 53.6, p=0.0067). The bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) demonstrated 36% efficacy against severe rotavirus gastroenteritis in Indian infants.
Synapse has enriched 10 related papers. Consider them for comparative context: